NaviGate Cardiac Structures Inc. (“NCSI”) reports first patient treated for mitral regurgitation (“MR”)


Nov 23, 2015   •  Announcement

LAKE FOREST, Calif. – NaviGate Cardiac Structures Inc. (NCSI) announced today that a First-In-Human implant of it’s catheter-guided, mitral-valved stent into a beating heart was performed successfully in a 53-year-old male patient presenting with severe 4+* MR. The interventional team was led by Dr. Cristián Baeza Prieto at San Borja Arriarán Hospital in Santiago, Chile, on October 26, 2015. The patient is thriving at four weeks post-procedure. …

About NaviGate

NaviGate Cardiac Structures Inc. (www.navigatecsi.com) is an early-stage company focused on developing transcatheter solutions for the less-invasive treatment of atrioventricular valve regurgitation. The NaviGate valved-base technology was licensed from Cleveland Clinic and further modified and developed by NCSI.

Leave a Reply